Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

CABA-201 gets FDA orphan drug status as scleroderma treatment

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Cabaletta Bio’s cell therapy CABA-201 as a treatment for adults with hard-to-treat systemic sclerosis (SSc), or scleroderma. Orphan drug designation is intended to support the accelerated development of investigational treatments for rare diseases, defined as…

1st patient dosed in Phase 2 trial of efzofitimod for SSc-ILD

Dosing has begun in a Phase 2 clinical trial evaluating aTyr Pharma’s efzofitimod, a first-in-class therapy for people with interstitial lung disease (ILD) associated with systemic sclerosis (SSc) — together known as SSc-ILD. Recruitment for the proof-of-concept EFZO-CONNECT study (NCT05892614), which aims to enroll up to 25…

2 microRNAs together may be useful disease biomarkers: Study

The levels of two microRNAs are found altered in the bloodstream of adults with systemic sclerosis (SSc) compared with healthy people, according to a new study that suggests using these molecules as biomarkers of the disease. Elevated levels of one of them, called miR-21, is associated with scar formation,…

Plasma exchange seen to help in scleroderma renal crises

Plasma exchange helped reduce high blood pressure linked to scleroderma renal crisis (SRC) — a potentially life-threatening complication marked by abrupt blood pressure changes and acute kidney failure — in patients unresponsive to standard treatment, a case series study reported. Despite these successes, most patients still had impaired kidney…